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Review Epilepsy in patients with Angelman syndrome
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Abstract
Angelman syndrome (AS) is a neuro-behavioural, genetically determined condition, characterized by ataxic jerky 
movements, happy sociable disposition and unprovoked bouts of laughter in association with seizures, learning 
disabilities and language impairment. Most of the cases are hardly diagnosed during infancy as jerky movements, the 
cardinal sign, appear later in childhood.
AS is caused by a variety of genetic mechanisms involving the 15q 11-13 chromosome. About 70% of cases are due to 
a "de novo" interstitial deletion in the long arm region, arising on the maternally inherited chromosome. The diagnosis 
is confirmed by methylation test or by mutation analysis of UBE3A gene. The deletion phenotype is generally linked to 
a more severe clinical picture in that 95% of patients manifest more severe seizures, severe mental and motor 
retardation, dysmorphic features and microcephaly.
The pathogenesis of epilepsy in AS is still not fully understood. The presence in the commonly deleted region of a 
cluster of genes coding for 3 subunits of the GABAa receptor complex has lead to the hypothesis that GABA 
neurotransmission is involved.
Epilepsy, often severe and hard to control, is present in 85% of patients within the first three years of life, although less 
than 25% develop seizures during the first year. It was observed that febrile seizures often precede the diagnosis. Most 
frequent types are atypical absences, generalized tonic-clonic, atonic or myoclonic seizures, with multiple seizure types 
occurring in 50% of deleted patients. There is still some doubt about the association with West syndrome.
The EEG abnormalities are not themselves pathognomonic of AS and both background activity and epileptic 
discharges vary even in the same patient with time. Nevertheless, the existence of some suggestive patterns should 
facilitate the early diagnosis allowing the correct genetic counselling for the family. Some drugs seems to act better 
than others, Valproate, ethosuximide and clonazepam giving the best results.
Introduction
Angelman syndrome (AS) is a neuro-behavioural, geneti-
cally determined condition, described in 1965 by Dr.
Harry Angelman, a British paediatrician[1].
Patients are now widely known for their behavioural
and motor pattern well defined as "happy puppet",
although this denomination is actually avoided because of
the possible derision meaning to the family. These chil-
dren indeed present ataxic jerky movements, happy
sociable disposition and unprovoked bouts of laughter, in
association with seizures, learning disabilities and lan-
guage impairment[2]. Characteristic facial features
include deep set eyes, pointed chin, macrostomia, wide-
spaced teeth, and brachycephaly. Blond hair and blue eyes
can appear unusual when compared to the familial phe-
notype.
The estimated frequency is 1/15000 - 1/20000 [3]. In
1995, Williams et al.[4] established the clinical criteria for
the diagnosis.
Most of the cases are hardly diagnosed during infancy
when the facial appearance can be not yet clear and subtle
signs as hands and fingers tremor, easy smile and feeding
difficulties are generally underestimated (Fig. 1). With
time, in early childhood, delayed milestones, without
appropriate language development, deceleration of head
growth, epilepsy and sleep disorders become evident.
The appearance of the typical jerky movements, the car-
dinal sign of late childhood picture, facilitates the diagno-
sis.
Genetics
AS is caused by a variety of genetic mechanisms involving
the 15q11-13 chromosome. About 70% of cases are due to
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a "de novo" interstitial deletion, involving the long arm
region of the maternally inherited chromosome[5]. In a
low percentage (3%) AS is linked to a paternal uniparental
disomy (UPD) in that the child has inherited both chro-
mosomes 15 from the father[6]. AS may also derive from
imprinting defects (ID) during gamethogenesis [7].
Another genetic mechanism was identified in the occur-
rence of mutations of the maternal UBE3A gene[8]. This
gene encodes the E6AP-3A ubiquitin protein ligase
involved in brain protein degradation[9]. Maternally
imprinted in the brain, it is expressed in cerebellum
Purkinjie cells, olphactory tracts and hippocampus[10].
UBE3A anomalies are present in 85% of AS with familial
recurrence and 15 -23% of sporadic ones. De novo muta-
tions occur in 70% of cases. A high incidence of gonadal
mosaicism has also been observed interesting both
maternal and paternal germline.
The clinical diagnosis is confirmed by methylation test
or, when this is negative, by the mutation analysis of
UBE3A gene. Nevertheless, in a small percentage (5-10%)
of subjects with a clinical diagnosis of AS, any cytogenetic
or molecular alteration is found[11]. These patients could
bear a not yet identified genetic anomaly involving
UBE3A activity or even have a wrong clinical diagnosis.
The deletion phenotype is generally linked to a more
severe clinical picture in that 95% of patients manifest a
worse seizures pattern, severe mental and motor retarda-
tion, dysmorphic features and microcephaly[12]. Patients
with UPD are less severely affected so that the diagnosis
is often suspected later[11]. Generally they reach walking
abilities, some interaction with the environment is
observed and only 20% of them present seizures. Patients
with imprinting anomalies have a even milder course
with less seizures and better communication skills[13].
UBE3A mutation patients are similar to deletion patients
as far as concerns seizures, microcephaly and absence of
speech.
Pathogenetic Hypoteses
The pathogenesis of epilepsy in AS is still not fully under-
stood. The presence in the commonly deleted region,
15q11-q13, of a cluster of genes coding for 3 subunits of
the GABAa receptor complex has lead to the hypothesis
that GABA neurotransmission is involved in AS[14].
All the involved genes are greatly expressed in several
areas of the embryonic and newborn brain. Anyhow, the
animal model, obtained by blocking these genes, shows
signs different from the clinical AS pattern and con-
versely almost 30% of AS patients are not deleted in that
specific region.
UBE3A gene codes for a ubiquitin protein ligase acting
in a pathway where proteins are marked to reach specific
proteasomes. Ubiquitin related enzymes are known to
increase during growth-factor induced neuronal differen-
tiation. Thus ubiquitin-mediated proteolysis might be
involved in posttranslational processing of some precur-
sor proteins that play a role in synaptogenesis and at syn-
aptic receptors level[9]. GABAa receptor is connected
with a chloride channel and acts inhibiting neurotrans-
mission. All these aspects can have a deep impact on a
developing brain and the forthcoming epilepsy although
the exact pathogenic effect is still unknown.
Patients with 15q11-q13 microdeletion generally show
more severe neurologic pictures. In the animal model a
thalamocortical dysfunction resulting from dysregulation
of synaptic GABAergic transmission was observed. This
finding might explain the typical EEG rhythmic pattern
seen in patients with AS [14].
The phenotypic differences between patients with
15q11-q13 microdeletions and those with imprinting
defect or UPD suggest that in the latter group the residual
expression of the gene can allow a less severe clinical pic-
ture [15].
Recent studies have stressed the overlapping manifesta-
tion of other genetic syndromes such as RTT. Samaco et
al.[16] suggested a possible role of MeCP2 in the regula-
tion of UBE3A and GABRB3 expression in mammalian
brain thus increasing the awareness of a possible link
between these two conditions.
Seizures
Seizures are present in 85% of patients within the first
three years of life[17], although less than 25% develop sei-
zures during the first year[18]. Onset of seizures has been
described at various ages, as early as one month up to 20
years[19].
Epilepsy is often severe. All types of seizures have been
described and in most cases they are hard to control and
recur in clusters, alternating with seizures free periods.
Figure 1 Subtle finger tremors. A five months old boy with An-
gelman syndrome and drug resistant infantile spasms.Fiumara et al. Italian Journal of Pediatrics 2010, 36:31
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Most frequent types are atypical absences, generalized
tonic-clonic, atonic or myoclonic seizures, with multiple
s e i z u r e  t y p e s  o c c u r r i n g  i n  5 0 %  o f  d e l e t e d  p a t i e n t s .
Among the main ictal pattern, are also complex partial
seizure, mainly occipital, [20] together with clonic unilat-
eral seizures[21].
It was observed that febrile seizures often precede the
diagnosis of AS[22] and that even moderate temperature
increases show a triggering effect[23]. Based on their own
experience, Galvan-Manso et al[24] refer that myoclonic
seizures are the most frequent type at onset (as observed
in 25% of their patients between 4 months and 5 years),
followed by atonic seizures (23%). Generalized tonic
clonic seizures (21%) and atypical absences (12%) were
observed around 3 years of age. Less frequently, seizures
at onset, in their series, were extension spasms (9%)
w i t h i n  t h e  1 s t  y e a r  o f  a g e ,  f l e x i o n  s p a s m s  ( 5 % )  a t  6
months and focal seizures (5%) at 1 year.
Pelc et al[25] stress that, despite the widespread opin-
ion, epileptic spasms are uncommon. Infantile spasms are
typical of West syndrome and are characteristically asso-
ciated with so called "hypsarrhythmic" EEG. Although
flexion or extension spasms are reported in AS, the EEG
pattern is not frankly hypsarrhythmic consisting of runs
of 2-3 c/s of high amplitude higher than 300 μV. A num-
ber of reports described the occurrence of Lennox-Gas-
taut syndrome but the runs of slow spike-waves
complexes seen in AS are usually rhythmic with a non-
convulsive status epilepticus.
Periods of reduced contact, reduction of motor activity
and cognitive impairment, suggestive of neurological
regression, might instead hide episodes of non-convulsive
or not detectable status epilepticus. Indeed, Valente et
al[22] registered status epilepticus (SE) in 15/18 (84%)
patients, myoclonic SE in 7/18 (15%). Guerrini et al[21]
consider the peculiar limbs tremor the epiphenomenon
of cortical myoclonus. Recently Elia [26] by polygraphic
studies, documented that myoclonic jerks are not corre-
lated with EEG paroxysmal abnormalities. This "myoclo-
nic status in non progressive encefalopathies (MSNE)" is
characterised by the association of absences, subcontinu-
ous jerks and brief myoclonic absences. This pattern can
be observed also in other genetic conditions such as
Prader-Willi, Wolf-Hirschhorn and Rett syndrome
(RTT). Moreover, like in Rett syndrome, in AS seizures
are often difficult to detect and distinguish from other
hyperkinetic movements. Indeed, sometimes, the differ-
ential diagnosis between girls with AS and those with
RTT can be difficult. Stereotyped hand movements,
microcephaly, absence of speech and poorly controlled
seizures, are shared signs. Periodic breath spells, hyper-
ventilation, small and cold hands and feet are more sug-
gestive for a diagnosis of RTT, but in some cases the final
word is reserved to the cytogenetic and molecular inves-
tigations[27].
EEG
The EEG does not show a standard pattern of anomalies
and both background activity and epileptic discharge
vary even in the same patient.
Nevertheless, some suggestive EEG anomalies and epi-
leptic crises can allow a early diagnosis.
Since 1988, Boyd et al[28] described three typical pat-
terns commonly observed in AS patients and present
both in the awake and in the sleeping state, regardless of
the clinical evidence of seizures:
1. persistent generalized rhythmic 4-6 Hz activity not
influenced by eye closure (differing from what is seen
in other conditions, where such stimulations succeed
in blocking the activity; it should be helpful in the dif-
ferential diagnosis for patients younger than 12
years).
2. rhythm delta activity of 2-3 Hz more evident in the
anterior regions, while spikes and sharp waves repre-
sent the inter-ictal discharge pattern. Moderate
amplitude and multifocal spikes appear during epilep-
tiform activity. Generalised slow activity is predomi-
nant.
3. spikes and sharp waves mixed with 3-4 Hz compo-
nents of amplitude higher than 200 μV mainly from
the posterior area and triggered by eye closure.
These patterns appear early in life, from the 4th month
of life, so they represent a precious tool for the early diag-
nosis. With time EEG abnormalities change and, accord-
ing to their experience and previous reports[11,19,23],
Laan et al[29] describe high voltage slow burst activity of
1-3 Hz mixed with high amplitude 4-6 Hz activity in chil-
dren younger than 4 years, passing to 4-6 Hz activity from
posterior regions mixed with spike and waves in follow-
ing years till puberty. Adult patients show a very slow
background rhythm, at times mixed with focal or multifo-
cal spikes.
The same Authors[29], in their series of 36 AS patients,
found 50% of them showing an intermittent and some-
times continuous run of rhythmic triphasic 2-3 Hz activ-
ity of high amplitude (200 - 500 μV) mainly from the
frontal regions and mixed with spikes or sharp waves
areas. Characteristically these triphasic waves occurred
in alert patients while in other conditions (i.e. metabolic
diseases) they are generally observed in comatous
patients.
In 45% of his patients with 15q11-q13 deletion and 30%
of those with UBE3A mutation, Elia [26] described
MSNE characterised by a slow background activity, sub-
continuous theta-delta activity involving the central
areas, or brief sequences of rhythmic delta waves withFiumara et al. Italian Journal of Pediatrics 2010, 36:31
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superimposed spikes mainly involving the parieto-occipi-
tal area and activated by eye-closure.
There is still some concern about the association of AS
and West syndrome.
Matsumoto et al[19] described young AS patients with
hypsharrhythmic EEG based on the finding of irregular
delta waves associated with moderate to high amplitude
epileptiform discharges with multifocal distribution.
Neurophysiological studies on larger series of patients,
made by Dan and Boyd[14], demonstrated that the EEG
pattern commonly seen in AS can be easily differentiated
from hypsharrhythmia, consisting of runs of 2-3 c/s activ-
ity of amplitude higher than 300 μV, from the frontal
regions. Valente et al[27] described as "hypsharrhythmic-
like variants" the observed EEG tracing characterized by
runs of high amplitude asynchronous delta activity asso-
ciated with multifocal spikes and sharp waves of moder-
ate amplitude. This pattern, although resembling
hypsharrhythmmia showed a predominance of slow
waves over the epileptiform discharges. Furthermore no
sleep/wake correlation was observed, while fragmenta-
tion is usually seen during sleep in hypsharrhythmia.
Moreover in West syndrome periods of suppression are
seen in the context of a more chaotic EEG[28].
The co-occurrence of complex absences and tonic sei-
zures with mental retardation is also misinterpreted as
Lennox-Gastaut syndrome manifestation. Once again the
accurate evaluation of the EEG pattern should help differ-
entiating these two conditions for the presence in AS of
rhythmic runs of slow spike-wave complexes[25].
Treatment
Different anticonvulsants have been used and drug resis-
tant epilepsy described in AS patients. Today there is
enough evidence that some drugs act better than others
and that often, (as in RTT patients) movement abnormal-
ities, tremors and attention deficit spells can be misinter-
preted as seizures given that the EEG anomalies persist
also in absence of crises.
F r o m  a n  a c c u r a t e  e v a l u a t i o n  o f  4 5  c a s e s ,  V a l e n t e  e t
al[30] reported a good control of crises with V alproate
(VPA) alone or in association with benzodiazepines
(fenobarbital PB or clonazepam CZP). Recurrent myoclo-
nic SE were best controlled by VP A and ethosuximide.
On the contrary, epilepsy was worsened by carbam-
azepine (CBZ), oxacarbazepine and vigabatrin[31]. Topi-
ramate (Franz et al[32]) and ethosuximide (Sugiura et
al[33]) were successful in small samples of AS patients
with drug resistant epilepsy.
Dion et al[34] evaluated Lamotrigine(LMT) efficacy in
5 patients with different types of seizures (myoclonic,
tonic clonic, atypical absences) unresponsive to other
drugs (VPA, Benzodiazepines, phenytoine, carbam-
azepine and topiramate) obtaining a good control in 3 of
them. The potential myoclonic effect of LMT limits its
possible use in these patients, and more case controlled
studies are needed.
Ketogenic diet was helpful in some children with
untreatable epilepsy[4]. Piracetam is said to be effective
in controlling distal myoclonus[26].
Non convulsive status epilepticus, which should be
early treated according to protocols, demonstrated a vari-
able response to treatment with benzodiazepines, ket-
amine and corticosteroids[35] in limited number of
patients.
Personal experience
Our series of patients with AS showed a seizures type dis-
tribution similar to that reported in Literature. All
patients had febrile seizures before the onset of a frank
epilepsy. Myoclonic seizures were the most frequent in
infancy, followed by atypical absences and tonic clonic
seizures. None had convulsive SE. Valproate and topira-
mate were preferentially used anticonvulsants but in the
majority of cases epilepsy was hardly controlled. The crit-
ical EEG showed parossistic 1-1.5 c/s discharges of spike-
waves complexes. The background activity was consti-
tuted by a persistent generalized 4-6 hz activity arising
from the temporo-parietal regions (Fig. 2a). With time
Figure 2 EEG at different ages. (a) Generalized burst of spike and 
spike waves with high amplitude, prevalent in the anterior regions, (b) 
Very slow background activity mixed with multifocal spikes.Fiumara et al. Italian Journal of Pediatrics 2010, 36:31
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the EEG pattern changed showing a very slow back-
ground activity mixed with multifocal spikes (Fig. 2b).
Besides these data, our personal experience suggests us
the importance of a early diagnosis in view of a possible
familial recurrence. Babies with AS, are initially easily
unrecognized as the facial and behaviour phenotype
become clear later in life. Seizures can occur as early as
the first few months and other more common diagnosis
are often considered (i.e. perinatal brain hypoxia, febrile
s e i z u r e s ,  B 6  u n r e s p o n s i v e  s e i z u r e s ) .  A t  t h a t  a g e ,  t h e
observation of fine finger tremors may represent the only
clue that should press the clinician to ask for genetic tests.
Later in life, in girls with microcephaly, seizures, stereo-
typed hand movements and hyperventilation Rett syn-
drome must be ruled out.
Nevertheless, a number of patient can remain unde-
fined on a molecular basis. We now are aware of another
condition, named Pitt-Hopkins syndrome with similar
clinical signs and we suggest to verify also this possible
diagnosis in AS and RTT cases without a molecular con-
firmation. Pitt-Hopkins syndrome, initially described in
1978 in two unrelated patients with mental retarda-
tion[36], is characterized by severe psychomotor delay,
seizures and recurrent episodes of hyperventilation,
acquired microcephaly and distinctive facial appearance:
large nose with high philtrum, cupid's bow lips, macros-
tomia and wide-spaced teeth. With time a progressive
protrusion of the lower face structures appear. This phe-
notype can easily suggest the diagnosis of AS being often
associated with happy demeanor, sleep disturbances and
seizures. EEG shows occipital or central delta waves
unusual for the age and, in older patients, pseudoperiodic
complexes during wakefulness mixed with spikes and
slow spike/waves.
Pitt-Hopkins syndrome is linked to a microdeletion of
chromosome 18q21 and mutations of the TCF4 gene[37].
This gene shows a widespread expression in developing
human embryos playing a role on cell fate determination
and differentiation during development. The impaired
development of the noradrenergic neurons pathway
might cause abnormal respiratory network inside the
brain.
Conclusion
Seizures are observed in the great majority of AS
patients, may have a early onset and are often refractory
to treatment. Atypical absences and myoclonic seizures
are common as well as non convulsive status epilepticus.
Different seizure types can occur in each patient. Hyper-
kinetic stereotypes and behavioural disturbances are at
risk to be misinterpreted and considered epileptic mani-
festations leading to unjustified overtreatment.
Whatever is the individual natural course of seizures,
EEG varies with age.
Laan et al[38] state that "EEG abnormalities are not
themselves pathognomonic of AS and have to be seen in
the appropriate clinical context". Anyhow, knowing the
existence of some suggestive patterns should facilitate the
early diagnosis allowing the correct genetic counselling
for the family.
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